Table 2 Association of height and ovarian cancer risk using observed height among 7657 participants

From: Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers

 

N/events

HR (95% CI)

P value

Per 10 cm increase in observed height

  All participants (confounding adjustment sequentially)

   Adjusted for principal components

7657/784

1.12 (0.97–1.29)

0.12

   Additionally adjusted for country

7657/784

1.15 (1.00–1.32)

0.06

   Additionally adjusted for birth cohort

7657/784

1.05 (0.91–1.21)

0.53

   Additionally adjusted for mutation status

7657/784

1.06 (0.92–1.22)

0.42

   Additionally adjusted for menopausal status

7657/784

1.07 (0.94–1.23)

0.31

   Additionally adjusted for parity and age at menarche

7090/724

1.09 (0.94–1.26)

0.24

 By mutation statusa

   BRCA1 carrier

4502/552

1.07 (0.91–1.24)

0.42

   BRCA2 carrier

3155/232

1.11 (0.85–1.45)

0.44

   Pinteraction

  

0.64

 By menopausal statusb

   Premenopausal

7657/105

1.02 (0.72–1.42)

0.93

   Postmenopausal

4328/679

1.09 (0.94–1.26)

0.27

   Pinteraction

  

0.71

 By tumour subtypec

   Serous

7360/319

1.07 (0.87–1.31)

0.52

   Non-serousd

7360/168

1.30 (1.01–1.68)

0.045

   Phet

  

0.24

 By tumour gradec

   Well or moderately differentiated

7252/111

1.12 (0.83–1.52)

0.46

   Poorly/undifferentiated

7252/268

1.15 (0.93–1.43)

0.19

   Phet

  

0.89

  1. HR hazard ratio, CI confidence interval
  2. aAdjusted for principal components, birth cohort, country of enrolment, and menopausal status in weighted Cox model
  3. bAdjusted for principal components, mutation status, birth cohort, and country of enrolment
  4. cAdjusted for principal components, birth cohort, country of enrolment, mutation status, and menopausal status
  5. dIncludes endometrioid, mucinous, clear cell, and other histologic types
  6. Bolded line refers to the model corresponding to our main results
Back to article page